[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612469":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":24,"locations":34,"responsibleParty":55,"collaborators":18,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":18,"enrollmentInfo":67,"targetDuration":18,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Masaryk Memorial Cancer Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Interventional","EXPERIMENTAL","screening of adverse effects of curative therapy + quality of life screening",[13],"Other: active screening of adverse effects of anticancer therapy based on specific questionnaire + quality of life screening",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","quality of life screening",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"active screening of adverse effects of anticancer therapy based on specific questionnaire + quality of life screening","Based on the Questionnaire for the Assessment of Difficulties after the completion of cancer treatment, the attending physician will assess the need for intervention and respond appropriately to the reported problems. Intervention is assessed as education by the physician, the use of medication, or referral of the patient to a specialized outpatient clinic.",[9],[25,30],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"Lenka Pavčíková, MUDr.","CONTACT","+420 543 136 136","lenka.pavcikova@mou.cz",{"name":31,"role":27,"phone":32,"phoneExt":18,"email":33},"Martina Lojová, Ph.D.","+420 543 136 232","martina.lojova@mou.cz",[35],{"facility":5,"status":36,"city":37,"state":18,"zip":38,"country":39,"countryCode":18,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Brno","656 53","Czechia",{"type":41,"coordinates":42},"Point",[43,44],16.60796,49.19522,{"lat":44,"lon":43},[47,48,52],{"name":31,"role":27,"phone":32,"phoneExt":18,"email":33},{"name":49,"role":27,"phone":50,"phoneExt":18,"email":51},"Iveta Selingerová, Ph.D.","+420 543 136 720","iveta.selingerova@mou.cz",{"name":53,"role":54,"phone":18,"phoneExt":18,"email":18},"Lenka Pavčíková, MD","PRINCIPAL_INVESTIGATOR",{"type":56,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100612469","cancer-survivors-program-100612469",false,"NCT07253987","Cancer Survivors Program","Cancer Survivors Program: Effectiveness of Monitoring Adverse Events After Completion of Curative Treatment for Breast and Prostate Cancer","SURV-QoL","Inclusion Criteria:\n\n* The patient understands the information provided and agrees to participate in the study.\n* Age 18 years or older.\n* Histologically confirmed invasive breast cancer or invasive prostate cancer.\n* Completion of the acute phase of curative oncological therapy:\n\n  * for breast cancer: curative surgery performed + completed neoadjuvant\u002Fadjuvant chemotherapy and completed adjuvant radiotherapy, if indicated\n  * for prostate cancer: completed radiotherapy with curative intent or radical prostatectomy performed (open, laparoscopic, robotic) or completed adjuvant radiotherapy after prostatectomy\n* The patient is available for follow-up within 12 months of enrollment in the study.\n\nExclusion Criteria:\n\n* Active ongoing oncological therapy (except for (i) adjuvant hormone therapy, (ii) adjuvant targeted therapy (anti-HER2 therapy, CDK4\u002F6i, PARPi, T-DM1), (iii) adjuvant immunotherapy)\n* Neoadjuvant\u002Fadjuvant therapy did not include chemotherapy (breast cancer).\n* Recurrence of cancer\n* Metastatic disease\n* History of other primary malignancy (except for non-melanoma skin cancer)","ALL","18 Years",{"count":68,"type":69},200,"ESTIMATED","INTERVENTIONAL",[72],"NA","The questionnaire for assessment of adverse events after completion of cancer treatment, which is being piloted at the Masaryk Memorial Cancer Institute, aims to detect a wide range of adverse effects early on, thus facilitating adequate intervention and planning of follow-up care for all cancer survivors.",[75,76],"Prostate Cancer Patients","Breast Cancer Patients",[78,79,80,81,82],"cancer survivors","breast cancer","prostate cancer","neo-\u002Fadjuvant chemotherapy","quality of life","2026-06-10",{"date":85,"type":86},"2026-06-11","ACTUAL",{"date":88,"type":86},"2025-05-05",{"date":90,"type":69},"2026-12-31",{"name":5,"class":6},1]